Immunovia AB (publ)
Immunovia AB (publ) (IMMVF) Financial Performance & Income Statement Overview
Review Immunovia AB (publ) (IMMVF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Immunovia AB (publ) (IMMVF) Income Statement & Financial Overview
Review Immunovia AB (publ) IMMVF income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $455000.00 | $235000.00 | $85000.00 | $156000.00 |
| Cost of Revenue | $30.50M | $0.00 | $0.00 | $0.00 |
| Gross Profit | -$30.04M | $235000.00 | $85000.00 | $156000.00 |
| Gross Profit Ratio | -$66.03 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $0.00 | $0.00 | $5.31M | $6.55M |
| SG&A Expenses | $30.57M | $0.00 | -$5.31M | $21.75M |
| Operating Expenses | $30.57M | $31.46M | $23.99M | $24.31M |
| Total Costs & Expenses | $30.57M | $31.46M | $23.99M | $24.31M |
| Interest Income | $33.21M | $0.00 | $0.00 | $21.36M |
| Interest Expense | $17000.00 | $19.84M | $1.69M | $147000.00 |
| Depreciation & Amortization | $1.28M | $7.56M | $1.60M | $2.98M |
| EBITDA | $4.37M | -$23.67M | -$22.31M | $181000.00 |
| EBITDA Ratio | $9.60 | -$100.73 | -$262.47 | $1.16 |
| Operating Income | -$30.12M | -$31.23M | -$23.91M | -$24.16M |
| Operating Income Ratio | -$66.20 | -$132.89 | -$281.26 | -$154.85 |
| Other Income/Expenses (Net) | $33.19M | -$19.84M | -$1.69M | $21.21M |
| Income Before Tax | $3.07M | -$51.07M | -$25.60M | -$2.95M |
| Income Before Tax Ratio | $6.75 | -$217.31 | -$301.14 | -$18.88 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $21.36M |
| Net Income | $3.07M | -$51.07M | -$25.60M | -$2.95M |
| Net Income Ratio | $6.75 | -$217.31 | -$301.14 | -$18.88 |
| EPS | $0.02 | -$0.73 | -$0.28 | -$0.07 |
| Diluted EPS | $0.02 | -$1.13 | -$0.57 | -$0.07 |
| Weighted Avg Shares Outstanding | $169.71M | $70.17M | $91.16M | $45.29M |
| Weighted Avg Shares Outstanding (Diluted) | $169.71M | $45.29M | $45.29M | $45.29M |
The company's financials show resilient growth, with revenue advancing from $156000.00 in Q1 2024 to $455000.00 in Q4 2024. Gross profit remained healthy with margins at -6603% in Q4 2024 compared to 100% in Q1 2024. Operating income hit -$30.12M last quarter, sustaining a consistent -6620% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $4.37M. Net income rose to $3.07M, while earnings per share reached $0.02. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan